Lingdong Quan1, Yijia Zhang1, Anand Dusad1, Ke Ren1, P Edward Purdue2, Steven R Goldring2, Dong Wang3. 1. Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 986025 Nebraska Medical Center, COP 3026, Omaha, Nebraska, 68198-6025, USA. 2. Hospital for Special Surgery, New York, New York, 10021, USA. 3. Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 986025 Nebraska Medical Center, COP 3026, Omaha, Nebraska, 68198-6025, USA. dwang@unmc.edu.
Abstract
PURPOSE: To investigate the efficacy and safety of N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-dexamethasone conjugate (P-Dex) in the collagen-induced arthritis (CIA) mouse model. METHODS: HPMA copolymer labeled with a near infrared fluorescence (NIRF) dye was administered to mice with CIA to validate its passive targeting to inflamed joints and utility as a drug carrier system. The CIA mice were treated with P-Dex, dexamethasone (Dex) or saline and the therapeutic efficacy and skeletal toxicity evaluated using clinical scoring and micro-computed tomography (μ-CT). RESULTS: The NIRF signal of the HPMA copolymer localized to arthritic joints consistent with its passive targeting to sites of inflammation. While the CIA mice responded more rapidly to P-Dex compared to Dex, the final clinical score and endpoint μ-CT analyses of localized bone erosions indicated that both single dose P-Dex and dose equivalent daily Dex led to comparable clinical efficacy after 30 days. μ-CT analysis of the proximal tibial metaphyses showed that P-Dex treatment was associated with significantly higher BMD and BV/TV compared to Dex and the saline control, consistent with reduced glucocorticoid (GC) skeletal toxicity. CONCLUSION: These results validate the therapeutic efficacy of P-Dex in the CIA mouse model. P-Dex treatment averted the adverse effects of GC's on systemic bone loss, supporting its utility in clinical development for the management of rheumatoid arthritis.
ract_title">PURPOSE: To investigate the efficacy and safety of N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-dexamethasone conjugate (P-Dex) in the collagen-induced arthritis (CIA) mouse model. METHODS:HPMA copolymer labeled with a near infrared fluorescence (NIRF) dye was administered to mice with CIA to validate its passive targeting to inflamed joints and utility as a drug carrier system. The CIA mice were treated with P-Dex, dexamethasone (Dex) or saline and the therapeutic efficacy and skeletaltoxicity evaluated using clinical scoring and micro-computed tomography (μ-CT). RESULTS: The NIRF signal of the HPMA copolymer localized to arthritic joints consistent with its passive targeting to sites of inflammation. While the CIA mice responded more rapidly to P-Dex compared to Dex, the final clinical score and endpoint μ-CT analyses of localized bone erosions indicated that both single dose P-Dex and dose equivalent daily Dex led to comparable clinical efficacy after 30 days. μ-CT analysis of the proximal tibial metaphyses showed that P-Dex treatment was associated with significantly higher BMD and BV/TV compared to Dex and the saline control, consistent with reduced glucocorticoid (GC) skeletaltoxicity. CONCLUSION: These results validate the therapeutic efficacy of P-Dex in the CIA mouse model. P-Dex treatment averted the adverse effects of GC's on systemic bone loss, supporting its utility in clinical development for the management of rheumatoid arthritis.
Authors: A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker Journal: J Bone Miner Res Date: 1987-12 Impact factor: 6.741
Authors: Xin-Ming Liu; Ling-Dong Quan; Jun Tian; Yazen Alnouti; Kai Fu; Geoffrey M Thiele; Dong Wang Journal: Pharm Res Date: 2008-07-23 Impact factor: 4.200
Authors: Lingdong Quan; Yijia Zhang; Bart J Crielaard; Anand Dusad; Subodh M Lele; Cristianne J F Rijcken; Josbert M Metselaar; Hana Kostková; Tomáš Etrych; Karel Ulbrich; Fabian Kiessling; Ted R Mikuls; Wim E Hennink; Gert Storm; Twan Lammers; Dong Wang Journal: ACS Nano Date: 2013-12-27 Impact factor: 15.881
Authors: Xin Wei; Fei Li; Gang Zhao; Yashpal Singh Chhonker; Christine Averill; Josselyn Galdamez; P Edward Purdue; Xiaoyan Wang; Edward V Fehringer; Kevin L Garvin; Steven R Goldring; Yazen Alnouti; Dong Wang Journal: Mol Pharm Date: 2017-04-05 Impact factor: 4.939
Authors: Zhenshan Jia; Gang Zhao; Xin Wei; Dexuan Kong; Yuanyuan Sun; You Zhou; Subodh M Lele; Edward V Fehringer; Kevin L Garvin; Steven R Goldring; Dong Wang Journal: J Control Release Date: 2020-05-20 Impact factor: 9.776
Authors: Melissa N Zimel; Chloe B Horowitz; Vinagolu K Rajasekhar; Alexander B Christ; Xin Wei; Jianbo Wu; Paulina M Wojnarowicz; Dong Wang; Steven R Goldring; P Edward Purdue; John H Healey Journal: Mol Cancer Ther Date: 2017-08-22 Impact factor: 6.261